Norwegian PCI Biotech's drug Amphinex shows anti-tumour effect in phase I/II study

Submit press release

Existing customer?
Log in

New customer?
Sign up

Latest Headlines
Research and Markets: The Report 'PV Innovation in North America'...
Research and Markets: Vietnam Telecommunications Services Market Report:...
Research and Markets: Indonesia Soft Drinks Review 2011: consumption,...
Northampton family thank Red Cross with generous donation to county...
Research and Markets: Malaysia Soft Drinks Review 2011: consumption,...
Simon Ward - The MPC is making another policy...

M2 Archive: Preview

You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.

Norwegian PCI Biotech's drug Amphinex shows anti-tumour effect in phase I/II study
19 January 2010 - Norwegian biopharmaceutical company PCI Biotech Holding ASA (OSL: PCIB) said today that strong anti-tumour response was observed in all patients from the second dose group in the phase I/II study of its proprietary photosensitiser Amphinex.
In the trial, Amphinex is used...

If you want to view the full text, you must first purchase archive credits.
Return to Archives
New Search